ALAMEDA, Calif., April 24, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today reported financial results for its first quarter ended March 31, 2007. At March 31, 2007, Avigen had approximately $66 million in financial assets, including cash, cash equivalents, and available-for-sale securities and restricted investments, compared with approximately $71 million at December 31, 2006. More complete financial results are detailed in the financial tables below.
